WVE News and Press, Wave Life Sciences Ltd. From 06/26/23

2023-06-26 08:58:49 ET Wave Life Sciences ( NASDAQ: WVE ) said on Monday that it had joined the Russell 2000 and Russell 3000 indexes as a part of the annual reconstitution, effective after the U.S. market opens on June 26. Press Release For further details...

CAMBRIDGE, Mass., June 26, 2023 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage RNA medicines company committed to delivering life-changing treatments for people battling devastating diseases, today announced that the company has been added to the small-cap Russell 200...

2023-06-21 10:00:50 ET Summary Recent developments have created some uncertainties for Wave Life Sciences in its clinical programs. The discontinuation of the WVE-004 program corroborates a revised rating of hold on the company in my view. Investors should watch for updates on...

2023-05-23 08:12:07 ET Wave Life Sciences ( NASDAQ: WVE ) announced Tuesday it decided to halt further development of its neurology candidate WVE-004 after a failure in a Phase 1/2 trial for certain patients with amyotrophic lateral sclerosis (ALS) and dementia. WVE shares fell ~2...

Potent and durable target engagement observed across cohorts, including with 10 mg doses administered every 12 weeks which were also generally safe and well-tolerated WVE-004 did not show clinical benefit compared with placebo; additionally, poly(GP) reductions did not correlate with cl...

Presentations include new data showing WVE-006 improved markers of liver disease in mice; WVE-006 is a first-in-class RNA editing therapeutic for alpha-1 antitrypsin deficiency (AATD) which is designed to restore healthy, wild-type AAT protein Best-in-class exon skipping clinical data f...

2023-05-03 13:48:06 ET Wave Life Sciences Ltd. (WVE) Q1 2023 Earnings Conference Call May 03, 2023, 08:30 AM ET Company Participants Kate Rausch - VP, IR and Corporate Affairs Paul Bolno - President and CEO Anne-Marie Li-Kwai-Cheung - Chief Development Officer ...

2023-05-03 07:55:34 ET Wave Life Sciences press release ( NASDAQ: WVE ): Q1 GAAP EPS of -$0.27 misses by $0.23 . Revenue of $12.93M (+638.9% Y/Y) misses by $25.67M . As of March 31, 2023, Wave had $207.6 million in cash and cash equivalents, as compared to $88....

Emerging leader in RNA medicines with multi-modal discovery and development platform and first-in-class RNA editing programs Rapidly advancing toward 2023 CTA submissions and first-in-human study for WVE-006, the industry’s first RNA editing clinical candidate Planning fo...

2023-05-02 13:14:01 ET Wave Life Sciences ( NASDAQ: WVE ) is scheduled to announce Q1 earnings results on Wednesday, May 3rd, before market open. The consensus EPS Estimate is -$0.04 (+93.5% Y/Y) and the consensus Revenue Estimate is $38.6M (+2105.7% Y/Y). Over the las...